Caitlin W Hicks1, Elizabeth Selvin2. 1. Division of Vascular Surgery and Endovascular Therapy, Johns Hopkins University School of Medicine, 600 N Wolfe Street, Halsted 668, Baltimore, MD, 21287, USA. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 2024 E. Monument St., Suite 2-600, Baltimore, MD, 21287, USA. eselvin@jhu.edu.
Abstract
PURPOSE OF REVIEW: Diabetic peripheral neuropathy eventually affects nearly 50% of adults with diabetes during their lifetime and is associated with substantial morbidity including pain, foot ulcers, and lower limb amputation. This review summarizes the epidemiology, risk factors, and management of diabetic peripheral neuropathy and related lower extremity complications. RECENT FINDINGS: The prevalence of peripheral neuropathy is estimated to be between 6 and 51% among adults with diabetes depending on age, duration of diabetes, glucose control, and type 1 versus type 2 diabetes. The clinical manifestations are variable, ranging from asymptomatic to painful neuropathic symptoms. Because of the risk of foot ulcer (25%) and amputation associated with diabetic peripheral neuropathy, aggressive screening and treatment in the form of glycemic control, regular foot exams, and pain management are important. There is an emerging focus on lifestyle interventions including weight loss and physical activity as well. The American Diabetes Association has issued multiple recommendation statements pertaining to diabetic neuropathies and the care of the diabetic foot. Given that approximately 50% of adults with diabetes will be affected by peripheral neuropathy in their lifetime, more diligent screening and management are important to reduce the complications and health care burden associated with the disease.
PURPOSE OF REVIEW: Diabetic peripheral neuropathy eventually affects nearly 50% of adults with diabetes during their lifetime and is associated with substantial morbidity including pain, foot ulcers, and lower limb amputation. This review summarizes the epidemiology, risk factors, and management of diabetic peripheral neuropathy and related lower extremity complications. RECENT FINDINGS: The prevalence of peripheral neuropathy is estimated to be between 6 and 51% among adults with diabetes depending on age, duration of diabetes, glucose control, and type 1 versus type 2 diabetes. The clinical manifestations are variable, ranging from asymptomatic to painful neuropathic symptoms. Because of the risk of foot ulcer (25%) and amputation associated with diabetic peripheral neuropathy, aggressive screening and treatment in the form of glycemic control, regular foot exams, and pain management are important. There is an emerging focus on lifestyle interventions including weight loss and physical activity as well. The American Diabetes Association has issued multiple recommendation statements pertaining to diabetic neuropathies and the care of the diabetic foot. Given that approximately 50% of adults with diabetes will be affected by peripheral neuropathy in their lifetime, more diligent screening and management are important to reduce the complications and health care burden associated with the disease.
Entities:
Keywords:
Lower extremity disease; Microvascular complications; Peripheral neuropathy; Type 1 diabetes; Type 2 diabetes
Authors: William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan Journal: N Engl J Med Date: 2002-02-07 Impact factor: 91.245
Authors: Susan Storey; Andrea Cohee; Diane Von Ah; Eric Vachon; Noah R Zanville; Patrick O Monahan; Timothy E Stump; Victoria L Champion Journal: J Patient Cent Res Rev Date: 2020-10-23
Authors: Michael D Staudt; Tarun Prabhala; Breanna L Sheldon; Nicholas Quaranta; Michael Zakher; Ravneet Bhullar; Julie G Pilitsis; Charles E Argoff Journal: J Diabetes Sci Technol Date: 2020-08-28
Authors: Michelle Doose; Jennifer Tsui; Michael B Steinberg; Cathleen Y Xing; Yong Lin; Joel C Cantor; Chi-Chen Hong; Kitaw Demissie; Elisa V Bandera Journal: Cancer Causes Control Date: 2021-01-06 Impact factor: 2.506
Authors: Caitlin W Hicks; Dan Wang; Kunihiro Matsushita; John W McEvoy; Robert Christenson; Elizabeth Selvin Journal: Diabetes Res Clin Pract Date: 2022-01-20 Impact factor: 5.602